Holen Sie sich die Stockscreener-App
42.83
0.12%
0.05
Vorhandelsmarkt:
42.92
0.09
+0.21%
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
10 Biotech Stocks Screaming a Buy - Insider Monkey
Wolfe Research Initiates Coverage on BBIO with Outperform Rating - GuruFocus
Wolfe Research Initiates Coverage on BBIO with Outperform Rating | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Gains Positive Outlook with Strong Transthyreti - GuruFocus
Wolfe Research Initiates Coverage on BridgeBio Pharma With Outperform Rating, $49 Price Target - MarketScreener
BridgeBio (BBIO) Receives Outperform Rating from Wolfe Research | BBIO Stock News - GuruFocus
BridgeBio Pharma stock reaches 52-week high at $40.45 By Investing.com - Investing.com South Africa
BridgeBio Pharma stock reaches 52-week high at $40.45 - Investing.com
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright - MSN
BridgeBio Pharma’s SWOT analysis: stock poised for growth amid challenges - Investing.com
When the Price of (BBIO) Talks, People Listen - news.stocktradersdaily.com
Cantor Fitzgerald Comments on BBIO FY2026 Earnings - Defense World
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
BridgeBio Pharma (NASDAQ:BBIO) Given New $56.00 Price Target at HC Wainwright - Defense World
Day 8 of Gains Streak for BridgeBio Pharma Stock with 21% Return (vs. 42% YTD) [6/9/2025] - Trefis
BridgeBio stock holds Buy rating, price target at $56H.C. Wainwright - Investing.com Canada
BridgeBio Pharma (BBIO) Sees Price Target Increase by HC Wainwri - GuruFocus
BridgeBio (BBIO) Price Target Raised to $56 by H.C. Wainwright | - GuruFocus
Transcript : BridgeBio Pharma, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
BridgeBio Pharma (BBIO) Sees Price Target Increase by HC Wainwright & Co. | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Price Target Raised to $56 by H.C. Wainwright | BBIO Stock News - GuruFocus
Breakthrough Growth in Transthyretin Amyloid Cardiomyopathy - openPR.com
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN
BridgeBio Pharma stock hits 52-week high at $39.58 By Investing.com - Investing.com South Africa
BridgeBio Pharma stock hits 52-week high at $39.58 - Investing.com Australia
BMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying Competition - MSN
Piper Sandler maintains overweight rating on BridgeBio Pharma stock - Investing.com
Piper Sandler maintains overweight rating on BridgeBio Pharma stock By Investing.com - Investing.com UK
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - MSN
BridgeBio price target raised to $42 from $37 at BMO Capital - Yahoo Finance
BMO Capital raises BridgeBio Pharma stock price target to $42 By Investing.com - Investing.com UK
BridgeBio (BBIO) Target Price Raised by BMO Capital | BBIO Stock News - GuruFocus
Exploring High Growth Tech Stocks In The US Market - simplywall.st
BridgeBio: New Data Bolsters The Bull Case (NASDAQ:BBIO) - Seeking Alpha
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - The Manila Times
BridgeBio Management Reveals Latest Genetic Disease Strategy at Goldman Sachs Healthcare Conference 2025 - Stock Titan
BridgeBio Pharma (NASDAQ:BBIO) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Nuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - simplywall.st
BridgeBio Pharma’s SWOT analysis: stock soars on Attruby success, pipeline potential - Investing.com Nigeria
Propionic Acidemia Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Bridge Bio Pharma, HemoShear Therapeutics, Moderna Therapeutics - Barchart.com
Cetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
The Play On BridgeBio Pharma: Great Expectations For Attruby (NASDAQ:BBIO) - Seeking Alpha
BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - Insider Monkey
Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - marketscreener.com
BridgeBio (BBIO) Shares Positive Phase 3 Study Data | BBIO Stock News - GuruFocus
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | BBIO Stock News - GuruFocus
Breakthrough: New ATTR-CM Treatment Cuts Heart Complications by 43%, Shows Fastest Clinical Benefits Ever - Stock Titan
BridgeBio’s acoramidis shows promise in ATTR-CM study By Investing.com - Investing.com Nigeria
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):